Reviewing Sunesis Pharmaceuticals (SNSS) & Fibrocell Science (FCSC)
Sunesis Pharmaceuticals (NASDAQ: SNSS) and Fibrocell Science (NASDAQ:FCSC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.
This table compares Sunesis Pharmaceuticals and Fibrocell Science’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Sunesis Pharmaceuticals has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Fibrocell Science has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500.
Valuation and Earnings
This table compares Sunesis Pharmaceuticals and Fibrocell Science’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sunesis Pharmaceuticals||$2.54 million||56.09||-$38.02 million||($1.75)||-2.38|
|Fibrocell Science||$350,000.00||58.46||-$15.29 million||($1.82)||-0.43|
Fibrocell Science has lower revenue, but higher earnings than Sunesis Pharmaceuticals. Sunesis Pharmaceuticals is trading at a lower price-to-earnings ratio than Fibrocell Science, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings for Sunesis Pharmaceuticals and Fibrocell Science, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sunesis Pharmaceuticals currently has a consensus target price of $4.16, suggesting a potential upside of 0.00%. Fibrocell Science has a consensus target price of $5.00, suggesting a potential upside of 532.91%. Given Fibrocell Science’s stronger consensus rating and higher possible upside, analysts clearly believe Fibrocell Science is more favorable than Sunesis Pharmaceuticals.
Institutional and Insider Ownership
38.2% of Sunesis Pharmaceuticals shares are held by institutional investors. Comparatively, 31.6% of Fibrocell Science shares are held by institutional investors. 10.2% of Sunesis Pharmaceuticals shares are held by company insiders. Comparatively, 2.1% of Fibrocell Science shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Fibrocell Science beats Sunesis Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.
Fibrocell Science Company Profile
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.